$AIMAug 31, 2026, 12:51 PMAI processed
AIM ImmunoTech wins U.S. patent for Ampligen+pembrolizumab combo, protection through Dec 2039
AI Summary
The USPTO granted AIM ImmunoTech a U.S. patent covering use of rintatolimod (Ampligen) in combination with pembrolizumab for treating cancer, with the broadest claim covering combinations that produce greater-than-additive anti-cancer effects; the patent expires December 20, 2039. The patent names multiple cancers including pancreatic (AIM's late-stage focus) and complements existing U.S., Netherlands and Japanese patents on Ampligen+PD-1/PD-L1 combinations, strengthening AIM's oncology IP estate, but the release contains no new clinical efficacy or regulatory data.
Positives
- USPTO issued a U.S. patent covering Ampligen combined with pembrolizumab, expiring Dec 20, 2039
- Broad claim covers combination therapy for many cancers and specifically names pancreatic cancer, aligning with AIM’s late-stage strategy
- Adds to existing U.S., Netherlands and Japanese patents covering Ampligen with PD-1/PD-L1 checkpoint inhibitors
Negatives
- No clinical trial results or new efficacy data were announced with the patent
- Patent protection does not equate to regulatory approval and enforcement/foreign IP protection may be uncertain